Latrepirdine for Alzheimers disease: Trials and tribulations

Future Neurology

Volumn 5, Issue 5, 2010, Pages 645-651

  Sabbagh, Marwan N ^a   Berk, Camryn ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimers disease; clinical trial; dementia; Dimebon; latrepirdine

Indexed keywords

ACETYLCHOLINESTERASE; DIMEBON; DONEPEZIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; SEROTONIN RECEPTOR; TACRINE;

ABDOMINAL DISTENSION; AGING; ALZHEIMER DISEASE; CELL SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; DIZZINESS; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EMBRYOTOXICITY; FATIGUE; HUMAN; HYPERKALEMIA; IN VITRO STUDY; IN VIVO STUDY; LEARNING; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MEMORY; MITOCHONDRIAL PERMEABILITY; NEPHROTOXICITY; NERVE FIBER GROWTH; NEUROPROTECTION; NIGHTMARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 77957113132     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.10.53     Document Type: Review

References (37)

1. Sabbagh MN, Shill HA: Latrepirdine, a potential novel treatment for Alzheimers disease and Huntingtons chorea. Curr. Opin. Investig. Drugs 11(1), 80-91 (2010).
2. Mayeux R: Genetic epidemiology of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20(3 Suppl. 2), S58-S62 (2006).
3. Yaari R, Corey-Bloom J: Alzheimers disease. J. Semin. Neurol. 27(1), 32-41 (2007).
4. Atwood CS, Obrenovich ME, Liu T et al.: Amyloid-b: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-b. Brain Res. Rev. 43, 1-16 (2003).
5. Trinh NH, Hoblyn J, Mohanty S, Yaffe K: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289, 210-216 (2003).
6. Sabbagh MN, Farlow MR, Relkin N, Beach TG: Do cholinergic therapies have disease-modifying effects in Alzheimers disease? Alzheimers Dement. 2, 118-125 (2006).
7. Auld DS, Kornecook TJ, Bastianetto S, Quirion R: Alzheimers disease and the basal forebrain cholinergic system: relations to b-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 68, 209-245 (2002).
8. Beal MF: Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58, 495-505 (2005).
9. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291(3), 317-324 (2004).
10. Cummings JL, Doody R, Clark C: Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 69, 1622-1634 (2007).
11. Bachurin S, Bukatina E, Lermontova N et al.: Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. NY Acad. Sci. 939, 425-435 (2001).
12. Bachurin S, Lermontova N, Shevtzova E, Serkova T, Kireeva E: Comparative study of tacrine and Dimebon action on mitochondrial permeability and b-amyloid-induced neurotoxicity. Neurochemistry 73(Suppl.), S185 (1999).
13. Galenko-Iaroshevski PA, Shadurski KS, Iliuchenok TI, Pasechnikov FG, Khanferian RA: [Anti-allergic properties of dimebon, fencarol and ketotifen in sensitization by common ragweed pollen.] Farmakol. Toksikol. 47(3), 75-78 (1984).
14. Shadurskaya SK, Khomenko AI, Perverzev VA: Neurotransmitter mechanisms of the action of the antihistamine Dimebon on the brain. AI Bull. Exp. Biol. Med. 101(6), 780-782 (1986).
15. Schaffhauser H, Mathiasen JR, Dicamillo A et al.: Dimebolin is a 5HT(6) antagonist with acute cognition enhancing activities. Biochem. Pharmacol. 78(8), 1035-1042 (2009).
16. Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO: Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca2+ channels. Bull. Exp. Biol. Med. 132(5), 1079-1083 (2001).
17. Yamashita M, Nonaka T, Arai T et al.: Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett. 583(14), 2419-2424 (2009).
18. Grigorev VV, Dranyi OA, Bachurin SO: Comparative study of action mechanisms of Dimebon and memantine on AMPA-and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull. Exp. Biol. Med. 136(5), 474-477 (2003).
19. Lermontova NN, Lukoyanov NV, Serkova TP, Lukoyanova EA, Bachurin SO: Dimebon improves learning in animals with experimental Alzheimers disease. Bull. Exp. Biol. Med. 129(6), 544-546 (2000).
20. Grigorev VV, Garibova TL, Voronina TA, Litvinova SA, Bachurin SO: Effects of the chronic administration of Dimebon on behavior and memory of SAMP 10 mice. Exp. Clin. Pharmacol. 72(1), 52-56 (2009).
21. Giorgetti M, Gibbons JA, Bernales S et al.: Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-d-aspartate receptor antagonism. J. Pharmacol. Exp. Ther. 333(3), 748-757 (2010).
22. Steele JW, Kim SH, Cirrito JR et al.: Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-b levels in vitro and in vivo. Mol. Neurodegener. 4, 51 (2009).
23. Gandy S, Cirrito J, Steele J et al.: Dimebon, a clinically promising drug for Alzheimers disease, regulates amyloid-b metabolism in cultured cells, in isolated nerve terminals, and in the interstitial fluid of the living rodent brain. Alzheimers Dement. 5(4 Suppl. 1), E5 (2009).
24. Golubeva MI, Shashkina LF, Proinova VA: Preclinical study of the safety of the antihistaminic drug Dimebon. IA Farmakol. Toksikol. Moscow 48(3), 114-119 (1985).
25. Tariot PN, Sabbagh MN, Flitman S, Reyes P, Taber L, Seely L: A safety, tolerability and pharmacokinetic study of Dimebon in patients with Alzheimers disease already receiving donepezil. Alzheimers Dement. 5(4 Suppl. 1), P251 (2009).
26. Doody RS, Gavrilova SI, Sano M et al.; Dimebon Investigators: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimers disease: a randomised, double-blind, placebo-controlled study. Lancet 372(9634), 207-215 (2008).
27. Cummings J, Doody R, Gavrilova S et al.: 18-month data from an open-label extension of a 1-year controlled trial of Dimebon in patients with mild-to-moderate Alzheimers disease. Alzheimers Dement. 4(4 Suppl.), T770-T771 (2008).
28. Cummings J, Doody R, Gavrilova S et al.: Dimebon stabilizes neuropsychiatric symptoms in Alzheimers disease: one year clinical trial results. Am. J. Geriatr. Psychiatry 16, SA111 (2008).
29. Doody R, Sano M, Aisen P, Seely L: Dimebon improves cognition, function, and behavior in patients with mild to moderate Alzheimers disease; results by disease severity of a 1 year, double blind, placebo-controlled trial. J. Am. Geriatr. Soc. 57(Suppl. 1), S122-S123 (2009).
30. Hendrix S, Selby B, Seely L, Cummings J: Disease modifying effect of Dimebon in Alzheimers disease: results from a 12-month study of Dimebon and a six-month open label period analyzed using a staggered start approach and a natural-history staggered start (NHSS) approach. J. Neurol. 72(11), Abstract P06.074 (2009).
31. McKee M, Bobak M, Rose R, Shkolnikov V, Chenet L, Leon D: Patterns of smoking in Russia. Tob. Control 7, 22-26 (1998).
32. Mitka M: Heart disease a global health threat. JAMA 291, 2533 (2004).
33. Leon DA, Saburova L, Tomkins S et al.: Hazardous alcohol drinking and premature mortality in Russia: a population based case-control study. Lancet 369(9578), 2001-2009 (2007).
34. Medivation Inc.: Medivation announces first patient dosed in Phase II trial with Dimebon for treating AD. Press release 2005 (2009) http://investors.medivation.com/ releasedetail.cfm?ReleaseID=448818
35. Medivation Inc.: Pfizer and Medivation announce results from two Phase III studies in Dimebon Alzheimers disease clinical development program (2010) http://investors.medivation.com/ releasedetail.cfm?ReleaseID=448818
36. WHO Regional Office for the Western Pacific: Smoking Statistics (2002) www.wpro.who.int/media-centre/fact-sheets/fs-20020528.htm
37. Fagan T: Dimebon disappoints in Phase III trial. Alzheimer Research Forum (2010) www.alzforum.org/new/detail.asp?id=2387